1-12 of 12
Yimin Qian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian, Sheryl M. Gough, Monica Andreoli, Mark Bookbinder, Gregory Cadelina, John Bradley, Emma Rousseau, Julian Chandler, Ryan Willard, Jennifer Pizzano, Craig M. Crews, Andrew P. Crew, John Houston, Marcia Dougan Moore, Ron Peck, Ian Taylor
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 44.
https://doi.org/10.1158/1538-7445.AM2021-44
Published: 01 July 2021
View article titled, Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer
Journal Articles

Abstract PS18-09: Novel chimeric small molecule AC682 potently degrades estrogen receptor with oral anti-tumor efficacy superior to fulvestrant

Wei He, Hui Zhang, Lorena Perkins, Lissette Bouza, Ke Liu, Yimin Qian, Jie Fan
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS18-09.
https://doi.org/10.1158/1538-7445.SABCS20-PS18-09
Published: 15 February 2021
View article titled, Abstract PS18-09: Novel chimeric small molecule AC682 potently degrades estrogen receptor with oral anti-tumor efficacy superior to fulvestrant
Journal Articles

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

John Hines, Schan Lartigue, Hanqing Dong, Yimin Qian, Craig M. Crews
Journal: Cancer Research
Cancer Res (2019) 79 (1): 251–262.
https://doi.org/10.1158/0008-5472.CAN-18-2918
Published: 02 January 2019
View article titled, MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
Open the PDF for MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53 in another window
Includes: Supplementary data
Journal Articles

Abstract 5076: IHC and flow cytometry quantifies BRD4 levels in surrogate tissues after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC

Sheryl M. Gough, Kanak Raina, Debbie Gordon, Ryan Willard, Martha Altieri, Angela Shen, Yimin Qian, Taavi Neklesa, Kevin Coleman, Ian Taylor
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5076.
https://doi.org/10.1158/1538-7445.AM2017-5076
Published: 01 July 2017
View article titled, Abstract 5076: IHC and flow cytometry quantifies BRD4 levels in surrogate tissues after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC
Journal Articles

Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Dyana T. Saenz, Warren C. Fiskus, Kanak Raina, Taghi Manshouri, Kevin G. Coleman, Yimin Qian, Andrew P. Crew, Angela Shen, Christopher P. Mill, Baohua Sun, Misun Kim, Agnieszka J. Nowak, Srdan Verstovsek, Craig M. Crews, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5067.
https://doi.org/10.1158/1538-7445.AM2017-5067
Published: 01 July 2017
View article titled, Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
Journal Articles

Abstract 4710: BRD4 degradation by PROTACs represents a more effective therapeutic strategy than BRD4 inhibitors in ovarian cancer

Kanak Raina, Jing Lu, Yimin Qian, Martha Altieri, Hanqing Dong, Jing Wang, Xin Chen, Andrew Crew, Kevin Coleman, Craig Crews, James Winkler
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4710.
https://doi.org/10.1158/1538-7445.AM2016-4710
Published: 15 July 2016
View article titled, Abstract 4710: BRD4 degradation by PROTACs represents a more effective therapeutic strategy than BRD4 inhibitors in ovarian cancer
Journal Articles

Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Jing Lu, Yimin Qian, Kanak Raina, Baohua Sun, Stephanie S. Krieger, Simrit Parmar, Srdan Verstovsek, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4699.
https://doi.org/10.1158/1538-7445.AM2016-4699
Published: 15 July 2016
View article titled, Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells
Journal Articles

Abstract LB-010: Hijacking the E3 ubiquitin ligase cereblon to create efficient BRD4 degraders

Jing Lu, Yimin Qian, Martha Altieri, Hanqing Dong, Jing Wang, Kanak Raina, Jim Winkler, Andy Crew, Kevin Coleman, John Hines, Craig Crews
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): LB-010.
https://doi.org/10.1158/1538-7445.AM2015-LB-010
Published: 01 August 2015
View article titled, Abstract LB-010: Hijacking the E3 ubiquitin ligase cereblon to create efficient BRD4 degraders
Journal Articles

Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine

Jiazhi Sun, Michelle A. Blaskovich, David Knowles, Yimin Qian, Junko Ohkanda, Ratna D. Bailey, Andrew D. Hamilton, Saïd M. Sebti
Journal: Cancer Research
Cancer Res (1999) 59 (19): 4919–4926.
Published: 01 October 1999
View article titled, Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: <subtitle>Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine</subtitle>
Open the PDF for Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: <subtitle>Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine</subtitle> in another window
Journal Articles

Inhibiting Ras Prenylation Increases the Radiosensitivity of Human Tumor Cell Lines with Activating Mutations of ras Oncogenes

Eric J. Bernhard, W. Gillies McKenna, Andrew D. Hamilton, Said M. Sebti, Yimin Qian, JunMin Wu, Ruth J. Muschel
Journal: Cancer Research
Cancer Res (1998) 58 (8): 1754–1761.
Published: 01 April 1998
View article titled, Inhibiting Ras Prenylation Increases the Radiosensitivity of Human Tumor Cell Lines with Activating Mutations of <em>ras</em> Oncogenes
Open the PDF for Inhibiting Ras Prenylation Increases the Radiosensitivity of Human Tumor Cell Lines with Activating Mutations of <em>ras</em> Oncogenes in another window
Journal Articles

GGTI-298 Induces G0-G1 Block and Apoptosis Whereas FTI-277 Causes G2-M Enrichment in A549 Cells

Karine Miquel, Anne Pradines, Jiazhi Sun, Yimin Qian, Andrew D. Hamilton, Saïd M. Sebti, Gilles Favre
Journal: Cancer Research
Cancer Res (1997) 57 (10): 1846–1850.
Published: 01 May 1997
View article titled, GGTI-298 Induces G<sub>0</sub>-G<sub>1</sub> Block and Apoptosis Whereas FTI-277 Causes G<sub>2</sub>-M Enrichment in A549 Cells
Open the PDF for GGTI-298 Induces G<sub>0</sub>-G<sub>1</sub> Block and Apoptosis Whereas FTI-277 Causes G<sub>2</sub>-M Enrichment in A549 Cells in another window
Journal Articles

Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion

Jiazhi Sun, Yimin Qian, Andrew D. Hamilton, Saïd M. Sebti
Journal: Cancer Research
Cancer Res (1995) 55 (19): 4243–4247.
Published: 01 October 1995
View article titled, Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion
Open the PDF for Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion in another window